Clinical Trial Update: Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial exploring metabolomic and BH3 profiling to identify novel methods for assessing treatment response in esophageal cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Esophageal Cancer
• Esophageal Squamous Cell Cancer

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Esophageal Cancer, Esophageal Adenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2018-10-30